Adaptive immunity for therapeutic gain. Regulatory T cells (Treg, R) work to control excessive inflammation and may be harnessed to control neuroinflammation in PD and other neurodegenerative diseases. Treg can modulate microglia and other immune cells away from proinflammatory responses to anti-inflammatory/homeostatic functions. Therefore, strategies aimed at inducing, boosting, or reprogramming Treg responses (e.g., functional transformation of Teff [E] to Treg, increasing nTreg numbers, or activating Treg in an antigen-specific manner) show promise as possible disease-modifying therapies. Treg can modulate immune responses via several mechanisms, including suppressing microglia activation, inducing microglia phenotypic switching (toward anti-inflammatory), killing activated cells (e.g., Teff and microglia), and inhibition of APC maturation and antigen presentation. All together, Treg may suppress innate and adaptive proinflammatory, neurotoxic immune responses and boost homeostatic, neurotrophic immune responses resulting in slowing of neurodegeneration and allowing repair of damaged neurons. Such strategies may help to slow or halt the progression of PD.